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The role of NMDA receptors in oligodendrocytes has been controversial. A new 
paper suggests that they play a key role in regulating glucose uptake in response to 
axonal glutamate release, thus regulating bi-directional metabolic cooperation between 
oligodendrocytes and axons.   
Myelinated axons face unique energetic challenges. During development, 
oligodendrocytes require a large amount of energy and carbon skeletons to construct myelin 
sheaths (Harris & Attwell, 2012). Furthermore, once a sheath is formed, it isolates most of the 
underlying axon from the energetic substrate glucose present in the extracellular fluid, and 
some axons are so long that the supply of new mitochondria and glycolytic enzymes from the 
soma may take weeks to years (Nave, 2010). This raises the question of where axons get 
their energy from, and how the energy supply can adapt to immediate energy needs. A paper 
in this issue of Neuron (Saab et al., 2016) reveals a novel NMDA receptor dependent 
mechanism that coordinates the transfer of energetic substrates between oligodendrocytes 
and axons, to aid the initial development of the myelin sheath and to ensure the health of the 
axon once it is myelinated. 
The role of NMDA receptors (NMDARs) in oligodendrocyte linage cells has been 
controversial. Originally they were thought to be absent, but three separate studies (Káradóttir 
et al. 2005; Salter & Fern 2005; Micu et al. 2006) suggested that glutamate could activate an 
NMDAR-mediated current and calcium influx into oligodendrocyte precursors and myelinating 
oligodendrocytes, and that the Ca2+ influx damages myelin in ischemia. The receptors were 
reported to contain weakly Mg2+-blocked subunits, allowing them to function even at the 
normal resting potential of oligodendrocytes. However, NMDAR expression is downregulated 
after the development of oligodendrocytes, and two previous studies reported that knock-out 
of the NR1 subunit did not produce a major effect on myelination. 
Saab et al. (2016) found that applying NMDA to cultured oligodendrocytes increased 
trafficking of the glucose transporter GLUT1 to the surface membrane, while conditional 
knock-out of the obligate NMDAR subunit NR1 in oligodendrocytes (driven by the CNP 
promoter which turns on during oligodendrocyte differentiation, between P5 and P10) led to a 
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fall in the amount of GLUT1 in myelin. This is consistent with exocytosis of glutamate from 
axons acting on NMDARs to maintain the level of GLUT1 in ensheathing oligodendrocytes 
(Fig. 1). Although how NMDAR activation increases GLUT1 level in the surface membrane 
was not investigated in depth, Saab et al. (2016) attributed this to an NMDAR-evoked [Ca2+]i 
rise, as has been reported to occur in the myelin sheath when axons are stimulated (Micu et 
al., 2016). It will be of interest to determine whether prevention of [Ca2+]i transients in 
oligodendrocytes affects their sheath formation. Knock-out of oligodendrocyte NMDARs 
starting after postnatal day 5 did not prevent a normal myelin sheath thickness being attained, 
but at postnatal day 20 the myelination of small optic nerve axons was delayed (conceivably, 
use of a Cre line that turns on earlier in oligodendrocyte development to delete NMDAR 
signalling might result in a larger delay). This delay is consistent with the finding, from a cell 
culture model of myelination, that upregulation of oligodendrocyte NMDARs by neuregulin or 
BDNF leads to myelination becoming faster and dependent on neuronal activity (Lundgaard 
et al., 2013). Presumably, therefore, release of glutamate by axonal action potentials activates 
NMDARs in oligodendrocyte lineage cells and increases their glucose uptake, as a result of 
which myelination is preferentially focused on active cells (Lundgaard et al., 2013; Mensch et 
al. 2015), rather than on inactive axons that are undergoing developmental pruning or belong 
to neurons undergoing apoptosis. 
Once inside the developing oligodendrocyte, glucose can be converted to ATP and 
acetyl-CoA, and used to synthesise lipids for myelination. However, acetyl-CoA can also be 
formed from lactate or from N-acetyl-aspartate (NAA, Fig. 1). NAA is expressed at a high level 
in axons and exported to oligodendrocytes, where a loss of the aspartoacylase enzyme that 
converts it to acetate and thus to acetyl CoA leads to a failure of myelination in Canavan 
disease (it will be of interest to determine whether NMDAR activation also increases NAA 
uptake into oligodendrocytes). Thus, during developmental myelination there is a two-fold 
metabolic support of oligodendrocytes by axons: provision of NAA, and upregulation of 
glucose uptake by activation of NMDARs in oligodendrocytes near active axons. 
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Once the myelin sheath is formed, the direction of this metabolic cooperation may be 
reversed. Most of the axon is isolated by the myelin from glucose in the extracellular space, 
and it has been proposed that axons are at least partly powered by a sequence of processes 
in which glycolysis in oligodendrocytes generates lactate (or possibly pyruvate), which is 
passed by monocarboxylate transporters (Fig. 1) to the ensheathed axon, where it can be 
used as a substrate in mitochondria (Fünfschilling et al. 2012; Lee et al. 2012). This is similar 
to the proposed astrocyte-neuron lactate shuttle, in which ATP use on glutamate uptake and 
recycling in astrocytes promotes astrocyte glycolysis and export of lactate to neurons (Fig. 1). 
Saab et al. (2016) extend this concept by suggesting that maintenance of oligodendrocyte 
glucose transport, through activation of NMDARs, is crucial for the function and long-term 
health of myelinated axons. Transmission of high frequency trains of action potentials failed 
more rapidly if NMDARs were blocked, or knocked out in oligodendrocytes, and ran down less 
rapidly if NMDARs were activated prior to the trains being stimulated. More dramatically, in 
the medulla and spinal cord of 1 year old mice with oligodendrocyte NMDARs deleted, 
descending white matter tracts exhibited astro- and microgliosis, myelin delamination and 
degenerating axons, and these were associated with deficits on a rotarod test, while by 19 
months of age a more severe neurological phenotype was apparent with generalised 
neuroinflammation and axonopathy.   
Activation of oligodendrocyte NMDARs may also be important in the more immediate 
response of the white matter to ischemia. Activation of oligodendrocyte NMDARs by glutamate 
released in ischemia was reported to raise oligodendrocyte [Ca2+]i and thus damage myelin 
sheaths (Káradóttir et al. 2005; Salter & Fern 2005; Micu et al. 2006). This view has been 
challenged by recent work (Hamilton et al. 2016) demonstrating that much of the NMDAR-
mediated current in oligodendrocytes in brain slices is generated indirectly by a [K+]o rise in 
the tissue, and that the ischemic [Ca2+]i rise is mediated by TRPA1 channels rather than by 
oligodendrocyte NMDARs. Nevertheless, it is surprising that Saab et al. (2016) found deletion 
of NMDARs to decrease action potential recovery after oxygen-glucose deprivation of the optic 
nerve - a phenotype rescued by superfusion with lactate. This was attributed to NMDAR 
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activation being needed to maintain glucose import into oligodendrocytes and downstream 
transfer of lactate to axons (although it is not clear whether the superfused lactate would be 
provided as rapidly to the ensheathed axon as lactate generated within oligodendrocytes). 
Interestingly, unlike NMDAR deletion, block of NMDARs with MK-801 during oxygen-glucose 
deprivation did not affect recovery of the action potential. This suggests that turnover of 
GLUT1 transporters in the oligodendrocyte membrane is slow, so that a brief removal of 
NMDAR activation does not lead to much decrease of glucose transport.    
The work of Saab et al. (2016) demonstrates that, in a sense, oligodendrocyte NMDARs 
act as “power switches”, controlling the flow of energetic substrates both to the 
oligodendrocytes themselves and to their ensheathed axons. This raises a number of exciting 
questions relating to the energetic design of the white matter and how it can be exploited 
therapeutically in diseases of great personal and economic impact, such as stroke, spinal cord 
injury, multiple sclerosis and the genetic leukodystrophies. First, how local is the trigger for the 
power switch: the model of Saab et al. envisages an axon signalling solely to its own sheath, 
but immunogold images indicate NMDAR expression in both the outer and inner margins of 
the sheath (Káradóttir et al. 2008; Micu et al. 2006), suggesting that oligodendrocytes could 
also respond to glutamate release from other cells. This might imply tract-specific in addition 
to axon-specific control of energy supply. Second, how is glial energy supply regulated by 
myelinated GABAergic axons (such as Purkinje cells): does GABA do the same job as 
glutamate (e.g. via GABAB receptors), or could glutamate be released by the GABAergic axon 
within the sheath? Third, what is the precise mechanism by which the GLUT1 density in the 
oligodendrocyte membrane is controlled, and on what time scale is the GLUT1 level increased 
or decreased when the axon firing frequency is altered? If a [Ca2+]i rise is needed to trigger 
GLUT1 trafficking to the surface membrane, could TRPA1 channels (which raise 
oligodendrocyte [Ca2+]i in ischemia: Hamilton et al., 2016) or Ca2+-permeable AMPA receptors 
also be involved in this control?  
Turning to therapy, could the long-term health of white matter tracts be promoted by 
activation of oligodendrocyte NMDARs (a strategy that inverts previous conceptual 
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approaches) or by increasing GLUT1 trafficking to the oligodendrocyte surface membrane? 
Could pharmacologically potentiating the expression or function of the monocarboxylate 
transporters that allow lactate to move from oligodendrocytes to axons be used to increase 
the energy supply to axons? How does expression of GLUT1 and the monocarboxylate 
transporters change with age, diabetes, Alzheimer’s disease or when new oligodendrocytes 
are formed after demyelination? At present, all we can say is that the metabolic coordination 
characterised by Saab et al. (2016) is likely to play a role in many neurological conditions.  
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Figure Legend 
Fig. 1. Metabolic cooperation in the CNS 
Glucose provided by the blood is imported into the extracellular fluid by glucose transporters 
(largely GLUT-1), and then taken up into astrocytes, oligodendrocytes and neurons. In 
astrocytes glucose is used to make ATP via glycolysis, and some of the pyruvate thus formed 
generates more ATP via oxidative phosphorylation in mitochondria, while some is converted 
to lactate that can be exported to neuronal dendrites and somata to generate ATP in their 
mitochondria. ATP expenditure on glutamate uptake (EAAT) and recycling is proposed to 
stimulate glycolysis and lactate export (the astrocyte-neuron lactate shuttle, the quantitative 
significance of which is controversial). In developing oligodendrocytes, glucose is similarly 
used to form ATP, but also donates carbon skeletons for the formation of acetyl CoA and thus 
myelin lipids. Axonal N-acetyl-aspartate (NAA) is also transferred to oligodendrocytes, 
possibly via the Na+-dependent dicarboxylate transporters NaC2 and NaC3 (also known as 
NADC3) and used to make acetyl CoA for myelination. In mature oligodendrocytes, lactate (or 
pyruvate) formed from glucose can be exported to neuronal axons via monocarboxylate 
transporters (MCT1 and 2), providing them with a substrate for oxidative phosphorylation. 
Glutamate release from active axons activates NMDARs in oligodendrocyte lineage cells 
which, probably via a [Ca2+]i rise, triggers an increase in the level of glucose transporters in 
the cell membrane. This provides oligodendrocytes with more glucose to make myelin, and to 
export as lactate to axons. 
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